


# Proven patency.

# Measurable value.



Overall weighted average primary patency

## GORE® PROPATEN® Vascular Graft



OVER  
**500,000**  
devices implanted



OVER  
**2,000**  
limbs studied



OVER  
**30**  
clinical publications

**LASTING**  
THROMBORESISTANCE  
**PROVEN**  
TECHNOLOGY

**CBAS HEPARIN SURFACE\*\***

Walk through the data –Explore the interactive data summary at [propatenperformance.com](http://propatenperformance.com)

\* Overall weighted average primary patency is based on data from 12 peer-reviewed publications meeting pre-determined inclusion criteria. Visit [propatenperformance.com](http://propatenperformance.com) to see inclusion criteria, explore the data, see publications, and request reprints.

\*\* CBAS Heparin Surface. W. L. Gore & Associates Web site. <https://www.goremedical.com/cbas/references>. Accessed July 30, 2018.

1. Dorigo W, Raffaele P, Piffaretti G. Results from an Italian multicentric registry comparing heparin-bonded ePTFE graft and autologous saphenous vein in below-knee femoro-popliteal bypasses. *Journal of Cardiovascular Surgery* 2012;53(2):187-193.
2. Monaca V, Battaglia G, Turiano SA, Tringale R, Catalfamo S. Sub popliteal revascularization. Criteria analysis for use of E-PT.F.E. (Propaten®) as first choice conduit. *Italian Journal of Vascular & Endovascular Surgery*. 2013;20(3):165-169.

W. L. Gore & Associates, Inc. • Flagstaff, AZ 86004 • [goremedical.com](http://goremedical.com)

Products listed may not be available in all markets.

CBAS is a trademark of Carmeda AB, a wholly owned subsidiary of W. L. Gore & Associates, Inc.  
GORE®, PROPATEN®, and designs are trademarks of W. L. Gore & Associates.  
© 2018 W. L. Gore & Associates, Inc. AX1267-EN1 DECEMBER 2018

